Direct reference authority for drug GMP letters taken away from FDA districts.Centers must decide to issue warning letters
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. District Offices no longer have direct reference authority for issuing human and animal drug GMP GMP (guanosine monophosphate): see guanine. warning letters and must have them cleared through the appropriate Center in addition to clearance by the Office of Chief Counsel, according to according to
1. As stated or indicated by; on the authority of: according to historians.
2. In keeping with: according to instructions.
3. a six-month progress report on the agency's "Pharmaceutical GMPs for the 21st Century Initiative," released Feb. 20.
While certain types of GMP letters--such as letters from "Team Biologics Biologics include a wide range of medicinal products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. " inspections and letters involving device design controls--have been free of District Office direct reference authority for some time, the rescission The abrogation of a contract, effective from its inception, thereby restoring the parties to the positions they would have occupied if no contract had ever been formed. By Agreement was officially extended to all drug GMP warning letters effective March 1.
Previously, District Offices had the authority to issue warning letters directly to firms when inspectional observations did not meet GMP regulations.
The impetus Impetus is a stimulus or impulse, a moving force that sparks momentum.
Impetus may also refer to:
Asked to explain what inconsistencies the agency is trying to eliminate, FDA replied: "As innovative manufacturing and control technologies are adopted in the pharmaceutical industry, it is important that FDA regulate them in a consistent way. Some of these technologies will be first encountered in FDA's inspection program and Center review of warning letters will help assure that FDA responds to any deficiencies in a consistent manner."
Additionally, the Centers will be evaluating the inspectional information supporting proposed warning letters, the agency stated. Regular analysis of this data will aid the Centers in identifying trends used to further develop a risk-based strategy towards GMP enforcement practices, FDA continued.
The agency hopes to use this analysis "to enhance policy, provide guidance, and establish training for the FDA field staff and regulated industry."
To provide guidance under the Initiative, the review of warning letters has its own working group, chaired by CDER's Fred Blumenschein. But unlike some other working groups under the Initiative, the Warning Letter Review Working Group has yet to issue a progress report.
Blumenschein told a Feb. 20 press briefing that the Center review will examine "two issues--technical competency COMPETENCY, evidence. The legal fitness or ability of a witness to be heard on the trial of a cause. This term is also applied to written or other evidence which may be legally given on such trial, as, depositions, letters, account-books, and the like.
2. and significance" of the violations. "The idea is ensure consistency both from a technical realm and significance."
The rescission of direct reference authority was one of the "first steps" of the Initiative to improve regulation of pharmaceutical manufacturers to be completed.
Other completed steps of the Initiative's short-term Short-term
Any investments with a maturity of one year or less.
1. Of or relating to a gain or loss on the value of an asset that has been held less than a specified period of time. goals included clarifying the agency's 21 CFR CFR
See: Cost and Freight Part 11 electronic submission and recordkeeping requirements, and "clarifying the language used to communicate deficiencies observed" during GMP inspections.
This latter step was addressed by the "483 Communications Working Group." The Group came up with the following language that will be added to FDA's website where any 483s and warning letters are posted in order to clarify the purpose and effect of the 483 and alert the recipient about how to object to an observation or how to bring new information to the agency's attention. The language reads:
"This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection A formal attestation or declaration of disapproval concerning a specific point of law or procedure during the course of a trial; a statement indicating disagreement with a judge's ruling. regarding an observation, or have implemented, or plan to implement, corrective action A corrective action is a change implemented to address a weakness identified in a management system. Normally corrective actions are instigated in response to a customer complaint, abnormal levels if internal nonconformity, nonconformities identified during an internal audit or in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above."
Complete details on the GMP Initiative six-month progress reports can be found at: http://www.fda.gov/cder/gmp/index.htm